Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

This study is currently recruiting participants.
Verified December 2012 by Alberta Health Services
Sponsor:
Information provided by (Responsible Party):
Alberta Health Services
ClinicalTrials.gov Identifier:
NCT01428739
First received: October 21, 2010
Last updated: December 10, 2012
Last verified: December 2012

October 21, 2010
December 10, 2012
December 2007
June 2013   (final data collection date for primary outcome measure)
MRS Correlation with Treatment Response [ Time Frame: Up to One Year ] [ Designated as safety issue: Yes ]
measuring choline, water and fat levels by proton magnetic resonance spectroscopy in breast tumors in response to treatment
Same as current
Complete list of historical versions of study NCT01428739 on ClinicalTrials.gov Archive Site
Correlation with Tumor Stage [ Time Frame: Up to One year ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer
Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

Correlation between MRS and Tumor Response Therapy in Breast Cancer.

Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
Device: MRS
Procedure
Other Name: Philips 3 Tesla MRI Scanner
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed diagnosed Breast cancer
  • Patient is 18 years or older
  • Karnofsky performance score > 70
  • No previously irradiated or recurrent breast cancer
  • No contraindication to MRS/MRI
  • Signed informed consent.
Both
18 Years and older
No
Contact: Nadeem Pervez, MBBS, FFRRCSI, FRCPC 780-432-8517 nadeem.pervez@albertahealthservices.ca
Canada
 
NCT01428739
23701
Yes
Alberta Health Services
Alberta Health Services
Not Provided
Principal Investigator: Nadeem Pervez, MBBS, FFRRCSI, FRCPC Cross Cancer Institute
Alberta Health Services
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP